THEUER CHARLES 4

What Happened
Charles Theuer, a director of 4D Molecular Therapeutics, was granted a derivative award covering 50,000 shares on June 17, 2026. The Form 4 lists the acquisition price as $0.00 (reported value $0), indicating a grant of equity (stock options) rather than a cash purchase or sale. This is a compensation award under the company’s non-employee director program and is routine director compensation, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-17; Form 4 filed 2026-06-18 (appears timely).
• Grant: 50,000-share derivative award (stock option); transaction price shown as $0.00.
• Vesting: 1/3 vests on June 17, 2027 and then in equal monthly installments until fully vested on June 17, 2029; options vest in full upon a Change in Control. (Footnotes F1 and F2)
• Shares owned after transaction: not stated in the provided excerpt of the filing.
• Nature: Award/grant under non-employee director compensation (routine); no 10b5-1, tax withholding, or late-filing flags noted in the excerpt.

Context
This was a compensation grant (derivative stock option award) for a non-employee director — common practice for board pay. For retail investors, grants signal executive/director alignment with shareholders but are routine and do not necessarily indicate near-term insider confidence. The filing does not show an exercise price or immediate sale of shares; exercise terms and any future stock purchases would be reported separately when exercised or sold.